Zusammenfassung
Der primäre Hyperaldosteronismus (PHA) gilt als häufigste Form der sekundären Hypertonie und ist durch eine vermehrte, autonome Aldosteronproduktion der Nebennierenrinde gekennzeichnet. Der PHA ist mit einer deutlich erhöhten kardiovaskulären Morbidität und Mortalität assoziiert. Eine frühe Diagnose und eine spezifische Therapie sind daher von entscheidender Bedeutung. Der Diagnosealgorithmus gliedert sich in das Screening, einen Bestätigungstest sowie die Subtypdiagnostik. Ein niedriges Renin ist ein wichtiger Hinweis für einen PHA, das Aldosteron kann hingegen normal oder erhöht sein. Leitlinien empfehlen eine Adrenalektomie für geeignete Patienten mit gesichertem unilateralen PHA. Bei etwa 37 % der Patienten kommt es postoperativ zu einer kompletten klinischen Heilung. Für die medikamentöse Therapie sind Mineralokortikoidrezeptorantagonisten Mittel der Wahl.
Abstract
Primary raldosteronism (PA) is the most common form of secondary hypertension and is caused by increased autonomic aldosterone production by the adrenal cortex. PA is associated with a significantly increased cardiovascular morbidity and mortality. An early diagnosis and specific treatment are therefore of crucial importance. The diagnostic algorithm consists of screening, a confirmatory test and subtype classification. Suppressed renin and normal or elevated aldosterone levels are diagnostic hallmarks of PA. The guidelines recommend adrenalectomy for eligible patients with confirmed unilateral PA. In about 37% of the patients adrenalectomy leads to a complete clinical cure. Mineralocorticoid receptor antagonists (MRAs) are recommended for pharmaceutical treatment.
Literatur
Stowasser M, Gordon RD (2016) Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev 96:1327–1384. https://doi.org/10.1152/physrev.00026.2015.-In
Monticone S, Burrello J, Tizzani D et al (2017) Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 69(14):1811–1820. https://doi.org/10.1016/j.jacc.2017.01.052
Hattangady NG, Olala LO, Bollag WB, Rainey WE (2012) Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 350:151–162
Funder JW (2017) Aldosterone and mineralocorticoid receptors—physiology and pathophysiology. Int J Mol Sci. https://doi.org/10.3390/ijms18051032
Hall ME, Hall JE (2018) 5‑pathogenesis of hypertension. In: Bakris GL, Sorrentino MJ (Hrsg) Hypertension: a companion to Braunwald’s heart disease, 3. Aufl. Elsevier, S 33–51
Hundemer GL, Curhan GC, Yozamp N et al (2018) Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 6:51–59. https://doi.org/10.1016/S2213-8587(17)30367-4
Savard S, Amar L, Plouin P‑F, Steichen O (2013) Cardiovascular complications associated with primary aldosteronism. Hypertension 62:331–336. https://doi.org/10.1161/HYPERTENSIONAHA.113.01060
Reincke M, Fischer E, Gerum S et al (2012) Epidemiology/population science observational study mortality in treated primary aldosteronism the German conn’s registry. Hypertension 60:618–624. https://doi.org/10.1161/HYPERTENSIONAHA
Hall JE, Granger JP, Smith MJ, Premen AJ (1984) Role of renal hemodynamics and arterial pressure in aldosterone „escape“. Hypertension 6:I183. https://doi.org/10.1161/01.HYP.6.2_Pt_2.I183
Ribstein J, Du Cailar G, Fesler P, Mimran A (2005) Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 16:1320–1325. https://doi.org/10.1681/ASN.2004100878
Hundemer GL, Curhan GC, Yozamp N et al (2018) Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72:658–666. https://doi.org/10.1161/HYPERTENSIONAHA.118.11568
Rossi GP, Bernini G, Desideri G et al (2006) Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48:232–238. https://doi.org/10.1161/01.HYP.0000230444.01215.6a
Khurshid KA, Weaver ME (2005) Conn’s syndrome presenting as depression. Am J Psychiatry 162:1226. https://doi.org/10.1176/appi.ajp.162.6.1226
Reincke M (2018) Anxiety, depression, and impaired quality of life in primary aldosteronism: why we shouldn’t ignore it! J Clin Endocrinol Metab 103:1–4
Funder JW, Carey RM, Mantero F et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:1889–1916. https://doi.org/10.1210/jc.2015-4061
Funder JW (2020) Primary Aldosteronism: the next decade. Hypertens 76:325–326
Byrd BJ, Turcu AF, Auchus RJ (2018) Primary aldosteronism: practical approach to diagnosis and management. Circulation 138:823–835. https://doi.org/10.1161/CIRCULATIONAHA.118.033597
Brown JM, Siddiqui M, Calhoun DA et al (2020) The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 173:10–20. https://doi.org/10.7326/M20-0065
Williams B, MacDonald TM, Morant SV et al (2018) Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY‑2 mechanisms substudies. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(18)30071-8
Citton M, Viel G, Rossi GP et al (2015) Outcome of surgical treatment of primary aldosteronism. Langenbecks Arch Surg 400:325–331. https://doi.org/10.1007/s00423-014-1269-4
Williams TA, Lenders JWM, Mulatero P et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5:689–699. https://doi.org/10.1016/S2213-8587(17)30135-3
Rye P, Chin A, Pasieka J et al (2015) Unadjusted plasma renin activity as a „first-look“ test to decide upon further investigations for primary aldosteronism. J Clin Hypertens 17:541–546. https://doi.org/10.1111/jch.12523
Baudrand R, Vaidya A (2018) The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int J Mol Sci. https://doi.org/10.3390/ijms19020546
Funder JW (2014) Sensitivity to aldosterone: plasma levels are not the full story. Hypertension 63:1168–1170
Baudrand R, Guarda FJ, Fardella C et al (2017) Continuum of renin-independent aldosteronism in normotension. Hypertension 69:950–956. https://doi.org/10.1161/HYPERTENSIONAHA.116.08952
Stowasser M, Ahmed AH, Pimenta E et al (2012) Factors affecting the aldosterone/renin ratio. Horm Metab Res 44:170–176
Guo Z, Poglitsch M, Cowley D et al (2020) Effects of ramipril on the aldosterone/renin ratio and the aldosterone/angiotensin II ratio in patients with primary aldosteronism. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.120.14871
Song Y, Yang S, He W et al (2018) Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. Hypertension 71:118–124. https://doi.org/10.1161/HYPERTENSIONAHA.117.10197
Giacchetti G, Ronconi V, Lucarelli G et al (2006) Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. Lippincott Williams & Wilkins
Morera J, Reznik Y (2019) Management of endocrine disease: the role of confirmatory tests in the diagnosis of primary aldosteronism. Eur J Endocrinol 180:R45–R58
Becker LS, Hinrichs MH, Werncke T et al (2021) Adrenal venous sampling in primary hyperaldosteronism: correlation of hormone indices and collimated C‑arm CT findings. Abdom Radiol 46:3471–3481. https://doi.org/10.1007/s00261-021-03003-0
Williams B, Macdonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 386:2059–2068. https://doi.org/10.1016/S0140-6736(15)00257-3
Jeunemaitre X, Chatellier G, Kreft-Jais C et al (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60:820–825. https://doi.org/10.1016/0002-9149(87)91030-7
Parthasarathy HK, Ménard J, White WB et al (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. https://doi.org/10.1097/HJH.0b013e3283455ca5
Gemeinsamer Bundesausschuss (2022) Erteilung von Aufträgen an die Expertengruppen Off-Label: Eplerenon bei primärem Hyperaldosteronismus, wenn eine Therapie mit Spironolacton nicht oder nicht mehr infrage kommt. https://www.g-ba.de/beschluesse/4935/. Zugegriffen: 25. März 2022
Huang W‑C, Chen Y‑Y, Lin Y‑H, Chueh JS (2021) Composite cardiovascular outcomes in patients with primary aldosteronism undergoing medical versus surgical treatment: a meta-analysis. Front Endocrinol. https://doi.org/10.3389/fendo.2021.644260
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Beger, H. Haller und F.P. Limbourg geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
Hermann Haller, Hannover
Joachim Hoyer, Marburg
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Beger, C., Haller, H. & Limbourg, F.P. Hochdruck und Nebenniere. Nephrologie 17, 233–238 (2022). https://doi.org/10.1007/s11560-022-00584-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-022-00584-9